Urinary and biliary stone formation pathways

Urinary and biliary stone formation pathways represent the complex physiological and biochemical sequences leading to the development of solid calculi in the renal and biliary systems. Urinary stone formation, or urolithiasis, is primarily driven by the supersaturation of urine with salts such as calcium oxalate, calcium phosphate, or uric acid, which then undergo nucleation, growth, and aggregation (StatPearls, 2023; Pearle et al., 2014). Biliary stone formation, or cholelithiasis, typically results from an imbalance in bile composition—specifically the supersaturation of cholesterol or bilirubin relative to bile salts and phospholipids—often involving transporters like ABCB4 and ABCG5/G8 (Lammert et al., 2016; StatPearls, 2023). These pathways are influenced by genetic predispositions, dietary factors, and metabolic conditions that alter the solubility of minerals and lipids. Drugs targeting these pathways, such as thiazide diuretics for urinary stones or ursodeoxycholic acid for gallstones, work by modifying the chemical environment to inhibit crystal formation or promote dissolution (Pearle et al., 2014; Lammert et al., 2016). Understanding these integrated pathways is vital for the clinical management of stone-related diseases and the prevention of complications like obstruction and chronic inflammation.

Other names

Urolithiasis and cholelithiasis pathwaysCalculogenesisNephrolithiasis and gallstone formation mechanisms

Drugs modulate these pathways by reducing the concentration of stone-forming solutes (e.g., calcium, uric acid, cholesterol), increasing the concentration of crystallization inhibitors (e.g., citrate), or improving the solubility and flow of fluids in the urinary and biliary tracts (Pearle et al., 2014; Lammert et al., 2016).